Notwithstanding positive clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial difficulty from pharmacy benefit managers. These insurers are https://saadbfpv915914.ampedpages.com/company-s-medication-faces-is-encountering-pbm-obstacles-the-copyrightination-at-coverage-disputes-69066539